{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "increases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ02550",
      "entity_text" : "Passeo-18 Lux DCB",
      "entity_type" : "protein"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uniprot:Q01105",
      "entity_text" : "set",
      "entity_type" : "protein"
    },
    "hypothesis_information" : true
  },
  "verbose_text" : "Passeo-18 Lux DCB safety and effectiveness are supported by a robust set of clinical evidence comparable to other devices with published clinical data, as indicated by the 12-month CD TLR rate (6.8%) in particular.",
  "reading_complete" : "2020-08-04T13:14:28Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-04T13:13:38Z",
  "trigger" : "supported",
  "evidence" : [ "Passeo-18 Lux DCB safety and effectiveness are supported by a robust set" ],
  "pmc_id" : "5944304",
  "score" : 0
}